CD19 Monoclonal Antibody (eBio1D3 (1D3)), Functional Grade, eBioscience™, Invitrogen™

Description

• Description: The eBio1D3 monoclonal antibody reacts with mouse CD19, a 95 kDa transmembrane glycoprotein
• CD19 is expressed by B cells during all stages of development excluding the terminally differentiated plasma cells
• Follicular dendritic cells also express CD19
• Together CD21, CD81, MHC class II, and CD19 form a multimolecular complex that associates with the BCR
• Signaling through CD19 induces tyrosine phosphorylation, calcium flux and proliferation of B cells
• Applications Reported: This eBio1D3 (1D3) antibody has been reported for use in flow cytometric analysis, and immunohistology staining of frozen tissue sections
• The eBio1D3 monoclonal antibody has also been reported to induce down-regulation of CD19, affecting the proportions of B-1a and B-2 B cells in mice
• Applications Tested: This eBio1D3 (1D3) antibody has been tested by flow cytometric analysis of mouse splenocytes
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Endotoxin: Less than 0.001 ng/ug antibody as determined by the LAL assay
• Storage and handling: Use in a sterile environment
• Filtration: 0.2 μm post-manufacturing filtered
• CD19 is a member of the immunoglobulin superfamily and has two Ig like domains
• The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lambda light chains
• CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage
• Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen
• The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias
• Lymphocytes proliferate and differentiate in response to various concentrations of different antigens
• The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors
• CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation
• Besides being a signal-amplifying coreceptor for the B cell receptor (BCR), CD19 can also signal independently of BCR co-ligation and is a central regulatory component upon which multiple signaling pathways converge
• Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.